Clifford A. Hudis, MD, FACP, on Enzalutamide in Androgen Receptor–Positive, Triple-Negative Breast Cancer
2014 San Antonio Breast Cancer Symposium
Clifford A. Hudis, MD, FACP, of Memorial Sloan Kettering Cancer Center, discusses findings from abstract P5-19-09, “Stage 1 results from MDV3100-11: A two-stage study of enzalutamide, an androgen receptor inhibitor, in advanced androgen receptor–positive triple-negative breast cancer,” presented by Tiffany A. Traina, MD.
Ismail Jatoi, MD, PhD, FACS, and Clifford A. Hudis, MD, FACS
Ismail Jatoi, MD, PhD, FACS, and Clifford A. Hudis, MD, FACS, discuss the role of ovarian suppression and hormonal therapy in premenopausal women.
Harold J Burstein MD PhD and Lisa A Carey MD
Harold J. Burstein, MD, PhD, of the Dana-Farber Cancer Institute and Lisa Carey, MD, of the UNC Lineberger Comprehensive Cancer Center, discuss:
- The TNT trial comparing docetaxel to carboplatin
- The CALGB trial on response rates after neoadjuvant chemo with or without carboplatin or bevacizumab
- Pembrolizumab in a phase Ib study
Lisa A. Carey, MD
Lisa A. Carey, MD, of UNC Lineberger Comprehensive Cancer Center, offers her thoughts on abstract S1-09, "A phase IB study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast cancer," presented by Rita Nanda, MD.
Matthew J. Ellis, MD
Matthew J. Ellis, MD, PhD, of the Baylor College of Medicine, offers a brief synopsis of his plenary lecture, "Genome-Directed Therapeutics for Endocrine Therapy–Resistant Estrogen Receptor–Positive Breast Cancer."
